Home › Funds › Frazier Life Sciences Management, L.P. › DSGN

Frazier Life Sciences Management, L.P. position in DSGN

DESIGN THERAPEUTICS INC · Health Care

Frazier Life Sciences Management, L.P. reported holding 1,809,854 shares of DSGN (DESIGN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$26.2M, representing 0.57% of its reported portfolio and ranking #28 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed DSGN holdings in 8 of the last 9 reported quarters, going back to Q2 2024.

Latest position (Q2 2026)1.81M sh
Reported value held$26.19M
Portfolio Weight0.57%
First reportedQ2 2024
Last changeNew
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Frazier Life Sciences Management, L.P.'s DSGN position evolved

Frazier Life Sciences Management, L.P. first disclosed a stake in DSGN in Q2 2024 at 1,195,179 shares (US$4.0M). The position peaked in Q2 2026 at 1,809,854 shares, worth US$26.2M. Across 8 filings, Frazier Life Sciences Management, L.P. increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 1,809,854 shares valued at US$26.2M. Notable position changes include a 58% increase in Q3 2024 (shares rose 15% over the following quarter), a 73% trim in Q4 2025 (shares rose 13% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 1.20M $4.00M New
Q3 2024 1.89M $10.18M Add
Q4 2024 1.95M $12.05M Add
Q1 2025 1.95M $7.54M Hold
Q2 2025 1.95M $6.58M Hold
Q3 2025 1.95M $14.71M Hold
Q4 2025 521.00K $4.89M Reduce
Q2 2026 1.81M $26.19M New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DSGN and 13F data

DSGN (DESIGN THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in DSGN — the largest reported positions include SR ONE CAPITAL MANAGEMENT, LP (US$94.4M), Logos Global Management LP (US$43.4M), BAKER BROS. ADVISORS LP (US$38.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DSGN

All DSGN fund holders →

FAQ

How long has Frazier Life Sciences Management, L.P. held DSGN?

Frazier Life Sciences Management, L.P. has disclosed DSGN holdings in 8 of the last 9 reported quarters, going back to Q2 2024.

What is Frazier Life Sciences Management, L.P.'s current position in DSGN?

As of Q2 2026, Frazier Life Sciences Management, L.P. holds 1.81M shares of DSGN (DESIGN THERAPEUTICS INC), valued at $26.19M, representing 0.57% of its reported portfolio and ranking #28.

Has Frazier Life Sciences Management, L.P. been buying or selling DSGN?

In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. newly opened its position in DSGN. The position peaked in Q2 2026 at 1.81M shares.

Which other funds hold DSGN?

Other major institutional holders of DSGN include SR ONE CAPITAL MANAGEMENT, LP, Logos Global Management LP, BAKER BROS. ADVISORS LP, among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.